About 50 Mg Doxorubicin Hydrochloride IP
Explore the excellence of 50 mg Doxorubicin Hydrochloride IP, a laureate in oncology offered in a kingly, customizable glass vial pack, containing lyophilized red crystalline powder for injection. Procured and manufactured under GMP-certified facilities, this injectable anticancer agent complies with Indian Pharmacopoeia (IP) standards and is compatible with most standard intravenous infusion media. Rapid dissolution, high potency, and strict cytotoxic handling enhance its profile. Distributed with prescription-only status, its use is reserved for clinical settings under expert supervision. Store below 25C and enjoy a shelf life of 24 months.
Therapeutic Use and Clinical Suitability
50 mg Doxorubicin Hydrochloride IP is expertly designed for hospital and clinical deployment under physician guidance. Suitable for chemotherapy in leukemia, lymphoma, and solid tumors, it is administered using the intravenous route with sterile water. This product's customizable solution ensures it meets rigorous hospital standards, making it suitable for professional treatment environments where top-tier efficacy is paramount.
Delivery Protocol, Payment, and Packaging Details
Dispatched efficiently from India's prime FOB ports, each kingly-packaged vial meets export quality. Packaging includes glass vials safely sealed for cytotoxic containment. Payment terms are customizable according to the proposal amount and delivery schedules are coordinated for seamless logistics. We ensure secure packaging and fast, reliable delivery tailored to distributor and supplier needs.
FAQ's of 50 Mg Doxorubicin Hydrochloride IP:
Q: How should 50 mg Doxorubicin Hydrochloride IP be stored before use?
A: Store the vials below 25C, protected from light and moisture. Do not freeze. Follow cytotoxic drug handling procedures to maintain product integrity.
Q: What is the primary application and benefit of this product in clinical settings?
A: 50 mg Doxorubicin Hydrochloride IP is used as a chemotherapeutic agent for various cancers, notably leukemia, lymphoma, and solid tumors. Its high potency and compatibility make it invaluable in combination regimens under strict medical supervision.
Q: When should the reconstituted solution be administered after preparation?
A: After reconstitution with sterile water for injection, the solution should be used promptly according to institutional guidelines, ensuring maximum potency and safety for the patient.
Q: Where can I procure this product and who is eligible to use it?
A: This product can be procured by hospitals, clinics, and authorized medical distributors. Administration is restricted to certified healthcare settings by physicians experienced in chemotherapy protocols.
Q: What precautions should be taken during the preparation and administration process?
A: Use appropriate cytotoxic handling precautions, including protective gloves and equipment. Avoid mixing with heparin or fluorouracil solutions and ensure infusion is performed in an equipped facility to manage potential complications.